中国P站

Oral Vaccines; Mucosal Adjuvants; Delivery Systems; Epithelial-Immune Crosstalk; Nanotechnology; Gut Microbiome; Oral Tolerance; Vaccine Efficacy; Immunogenicity; Personalized Medicine

Introduction

Oral vaccines represent a compelling alternative to traditional injections, offering ease of administration and the potential to induce mucosal immunity at the site of pathogen entry. Recent research has focused on enhancing the effectiveness of oral vaccines through various strategies[1].

These strategies include the use of mucosal adjuvants and novel delivery systems designed to improve immune responses and overall vaccine efficacy[1].

A study investigated a chitosan-based nano-adjuvant, demonstrating its ability to significantly enhance both mucosal and systemic immune responses against influenza infection[2].

Epithelial cells play a crucial role in shaping the mucosal immune response to oral vaccines[3].

Understanding the signaling pathways and molecular mechanisms involved in epithelial-immune cell communication is vital for developing more effective oral vaccines[3].

Furthermore, recombinant protein-based oral vaccines, combined with mucosal adjuvants, have shown promise in inducing strong protective immunity and reducing bacterial colonization in the gut[4].

However, challenges remain in oral vaccine development, including the need to overcome oral tolerance and improve vaccine efficacy[5].

The gut microbiome's impact on oral vaccine effectiveness is another area of active research[6].

Different microbial compositions can influence immune responses to orally administered antigens, suggesting the potential for personalized oral vaccines that consider individual microbiome profiles[6].

Nanotechnology offers innovative solutions for improving oral vaccine delivery, with nanoparticles protecting antigens from degradation and enhancing their uptake by immune cells[7].

Nanoparticle-based oral vaccines have demonstrated the ability to elicit robust immune responses and provide long-lasting protection[7].

Understanding the mechanisms of oral tolerance is essential for overcoming this barrier in oral vaccine development[8].

Specific adjuvants and delivery systems can promote immune activation in the gut, helping to bypass oral tolerance[8].

An oral vaccine candidate against norovirus has shown promising results, demonstrating good tolerability and inducing significant antibody responses in vaccinated individuals[9].

Finally, a deeper understanding of epithelial-immune crosstalk is crucial for enhancing mucosal immunity and oral vaccine efficacy[10].

Targeting these interactions holds the potential to improve vaccine effectiveness[10].

Description

The development of effective oral vaccines hinges on overcoming several biological barriers and optimizing immune responses in the gastrointestinal tract. Mucosal adjuvants and delivery systems are critical components in enhancing the immunogenicity and efficacy of oral vaccines[1]. These systems aim to protect antigens from degradation in the harsh gut environment and facilitate their uptake by immune cells[1]. Epithelial-immune crosstalk plays a pivotal role in modulating immune responses to orally delivered antigens, highlighting the importance of understanding these interactions for improved vaccine design[3, 10].

Chitosan-based nano-adjuvants have shown promise in enhancing the immunogenicity of oral influenza vaccines[2]. These adjuvants can significantly improve both mucosal and systemic immune responses, leading to enhanced protection against influenza infection[2]. Recombinant protein-based oral vaccines, particularly those expressing Spike protein receptor-binding domain, have demonstrated the ability to induce strong protective immunity against SARS-CoV-2 infection[4]. The gut microbiome also influences the effectiveness of oral vaccines, with different microbial compositions affecting immune responses to orally administered antigens[6]. This underscores the potential for personalized oral vaccines tailored to individual microbiome profiles[6].

Nanotechnology offers innovative solutions for improving oral vaccine delivery, with nanoparticles protecting antigens from degradation and enhancing their uptake by immune cells[7]. Nanoparticle-based oral vaccines have been shown to elicit robust immune responses and provide long-lasting protection[7]. However, oral tolerance remains a significant challenge in oral vaccine development[8]. Understanding the mechanisms of oral tolerance and developing strategies to overcome this barrier are crucial for improving vaccine efficacy[8].

Clinical trials of oral vaccine candidates, such as those against norovirus, have demonstrated promising results in terms of safety and immunogenicity[9]. These vaccines can induce significant antibody responses in vaccinated individuals, suggesting their potential as a preventive measure against norovirus infection[9]. The ongoing research and development efforts in this field are focused on addressing the challenges and maximizing the potential of oral vaccines to prevent a wide range of infectious diseases.

Conclusion

Oral vaccines are gaining attention due to their ease of administration and ability to induce mucosal immunity. Research emphasizes mucosal adjuvants and delivery systems for enhanced immune responses and vaccine efficacy, focusing on epithelial-immune crosstalk. Studies explore chitosan-based adjuvants for influenza vaccines, improving mucosal and systemic immunity. Epithelial cells' role in mucosal immunity is examined to develop effective oral vaccines. Recombinant protein vaccines with adjuvants show promise against bacterial pathogens and SARS-CoV-2. Gut microbiome's impact on vaccine effectiveness suggests personalized approaches. Nanotechnology improves antigen delivery and uptake, offering long-lasting protection. Overcoming oral tolerance is crucial, with adjuvants and delivery systems promoting gut immune activation. Oral norovirus vaccine trials demonstrate safety and antibody responses, indicating potential for prevention. Understanding epithelial-immune crosstalk enhances vaccine efficacy, targeting interactions for improvement. These advancements aim to expand the range of diseases preventable through oral immunization, addressing challenges like oral tolerance and optimizing delivery systems for robust immune responses. Strategies include mucosal adjuvants, nanoparticle delivery, and personalized approaches based on the gut microbiome, driving the development of more effective and accessible oral vaccines. The collective findings underscore the potential of oral vaccines to revolutionize immunization strategies.

References

1. Olga S, Mikhail VL, Alexander LT (2023) .Vaccines 11:1451.

   , ,

2. Deepika A, Sakshi S, Anil KV (2022) .Int J Biol Macromol 222:1658-1672.

   , ,

3. Mohammad K, Muhammad S, Umer A (2023) .Front Immunol 14:1122698.

   , ,

4. Xiaolei D, Joon K, Jaehyuk S (2021) .J Agric Food Chem 69:13274-13285.

   , ,

5. Marina R, Silvia C, Carlotta P (2019) .Autoimmun Rev 18:102367.

   , ,

6. Takeshi T, Kjersti AK, Kenya H (2020) .Immunity 52:41-56.

   , ,

7. Camilla F, A KK, Michael TM (2021) .Nat Rev Mater 6:275-294.

   , ,

8. Jan H, Vesna C, Benoit R (2022) .Mucosal Immunol 15:697-710.

   , ,

9. Robert LA, David IB, Chris DH (2019) .J Infect Dis 220:1323-1332.

   , ,

10. Yun KL, Bana J, Qun Y (2020) .Mucosal Immunol 13:567-579.

    , ,